Table 1.
mRNA | Primers sequence | CFA | SNI | |||
---|---|---|---|---|---|---|
Ispi vs Sham |
Contra vs Sham |
Ispi vs Sham |
Contra vs Sham |
|||
MeCP2 e1 | F | 5'-ggagagactggaggaaaagtca-3' | 137% ** | 158% * | 74% * | ns |
R | 5'-ccttcttaaacttcaggggtttc-3' | |||||
MeCP2 e2 | F | 5'-ctgtttgggagaagcagagg-3' | ns | 134% * | 85% * | ns |
R | 5'-tggtagctgggatgttaggg-3' | |||||
FKBP5 | F | 5'-caccctgagcctggagagag-3' | ns | ns | ns | ns |
R | 5'-gtgtcgccattactcgcagag-3' | |||||
SGK1 | F | 5'-gggctgtcttgtatgagatgc-3' | ns | ns | ns | ns |
R | 5'-gtgccttgctgagttggtg-3' | |||||
SULT1a1 | F | 5'-ccgaggagactgtggattc-3' | ns | ns | ns | ns |
R | 5'-gcatagtgggcatcaaagc-3' | |||||
DNMT1 | F | 5'-ggagtgtgtgaaagagaaa-3' | 112% * | 114% ** | 87% * | ns |
R | 5'-tagccttcctcagacaat-3' | |||||
DNMT3a | F | 5'-aattgtgtcttggtggat-3' | 125% * | 124% * | ns | ns |
R | 5'-actgagaatttgccatct-3' | |||||
DNMT3b | F | 5'-ggagacagcagacatctt-3' | ns | 131% * | ns | ns |
R | 5'-gtcactacagttcccattaac-3' | |||||
HDAC1 | F | 5'-cctcaccgaatccgaatg-3' | 120% * | 128% ** | ns | ns |
R | 5'-cgaatagaacgcaagaacttg-3' | |||||
HDAC2 | F | 5'-tcaagtttctacgatcaataagg-3' | ns | ns | ns | 90% * |
R | 5'-cttctccgacattaaatctctg-3' | |||||
HDAC5 | F | 5'-aagtacgttcaaggctaa-3' | 117% ** | 114% ** | 77% *** | ns |
R | 5'-cgactgctctcttcttaa-3' | |||||
β-Actin | F | 5'-agattactgccctggctccta-3' | ns | ns | ns | ns |
R | 5'-aggatagagccaccaatccac-3' | |||||
HGPRT | F | 5'-aggacctctcgaagtgttggatac-3' | ns | ns | ns | ns |
R | 5'-tgtagattcaacttgccgctgtc-3' |
* P < 0.05; ** P < 0.01; ns: non significant. CFA N = 5 in each group and SNI N = 7 in each group